Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-containing product was FDA approved on 7 May 1982.
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
Phase 1
Completed
- Conditions
- HIV InfectionsAnus Neoplasms
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 98
- Registration Number
- NCT00000764
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
Phase 1
Completed
- Conditions
- Epidermolysis Bullosa
- First Posted Date
- 2001-04-11
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00014729
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath